The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.
News|Articles|January 23, 2006
The joint is jumping...and teeming with new products
Like a Turkish bazaar, the exhibit floor of the recent ASHP midyear conference, drawing an eye-popping attendance of 20,000 registrants, showcased many new products for health-system pharmacists. Here are some of the new wares displayed at the Las Vegas show
Advertisement
Like a Turkish bazaar, the exhibit floor of the recent ASHP midyear conference, drawing an eye-popping attendance of 20,000 registrants, showcased many new products for health-system pharmacists. Here are some of the new wares displayed at the Las Vegas show:
Advertisement
Related to this article
The approval extends the medication to a younger pediatric population, marking the first FDA-approved treatment for children with this immunodeficiency.
ACIP changes, new court rulings, and coverage gaps threaten vaccines, pharmacists’ reimbursement, and children's access through Vaccine For Children.
As pouched products increase in popularity, researchers assess their pharmacology, harm-reduction potential, and initiation risk.
Adults with serious mental illness receive GLP-1 prescriptions at rates similar to or higher than their peers, though schizophrenia continued to lag.
Madeline Sutton, MD, MPH, FACOG, joins to discuss risks of HPV infection among women and how pharmacists can improve outcomes in this area.
In part 2, Vanessa Slowey explains the pharmacy industry’s need for due diligence as technology reinforces patient convenience in the 21st century.
A study found that age and physical comorbidities—not psychiatric diagnosis—were associated with nonpsychotropic polypharmacy.
Advertisement
Advertisement
Trending on Drug Topics
1
GLP-1 Prescribing Rose Among Adults With Serious Mental Illness
2
Scripted for Her: The Pharmacist's Role in HPV Prevention
3
AI, Automation Are Transforming Pharmacies into Proactive Care Hubs
4
Study Links Age and Comorbidities to Polypharmacy in Patients With Mental Illness
5